Roflumilast
Daliresp, ZORYVE
Phosphodiesterase 4 Inhibitor
NADAC/unit
$0.3118
No Shortage
Tier 1: 43.2%
PA Req: 73.9%
9 Manufacturers
17 ANDAs
indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.
vs. brand Daliresp: Generic saves up to 97% per unit
Generic Manufacturers
ALKEM LABORATORIES LTDARCUTIS BIOTHERAPEUTICS INCASTRAZENECA PHARMACEUTICALS LPAUROBINDO PHARMA LTDHETERO LABS LTD UNIT IIIMICRO LABS LTDMSN LABORATORIES PRIVATE LTDPRINSTON PHARMACEUTICAL INCSENORES PHARMACEUTICALS INCSTRIDES PHARMA GLOBAL PTE LTDZYDUS PHARMACEUTICALS USA INC
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.